AbbVie Inc (ABBV)

61.54
0.64 1.05
NYSE : Health Care
Prev Close 60.90
Open 61.15
Day Low/High 60.92 / 61.92
52 Wk Low/High 50.71 / 68.12
Volume 7.09M
Avg Volume 7.68M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 97.49B
EPS 3.10
P/E Ratio 16.21
Div & Yield 2.56 (4.30%)

Latest News

3 Portfolio Movers: AbbVie, Ford and GameStop

Two are up, one's down, let's see why.

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant

- New Phase 2 data presented at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers

New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA®)

New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA®)

- Data presented at the American Society of Hematology Annual Meeting show 48% overall response rate

Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA®) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma

Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA®) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma

- New data available for ibrutinib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and in first-line follicular lymphoma (FL)

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Healthcare Stocks Help Nasdaq Reach New Heights

Healthcare Stocks Help Nasdaq Reach New Heights

The Nasdaq rose 0.7% to an all-time high of 5,403. The S&P 500 was up 0.3%, and the Dow Jones Industrial Average gained 0.2%.

AbbVie Becomes #208 Most Shorted S&P 500 Component, Replacing Principal Financial Group

AbbVie Becomes #208 Most Shorted S&P 500 Component, Replacing Principal Financial Group

The most recent short interest data has been released for the 11/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

What Stocks to Buy as Markets Reach Record Levels

What Stocks to Buy as Markets Reach Record Levels

Investors can benefit from the record highs in the markets by picking individual stocks off of their highs, Matrix Asset Advisors David Katz said.

Merck Raises Dividend

We favor AbbVie and Pfizer in pharma sector.

2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio

2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio

These two pharmaceutical stocks offer great yields.

10 High-Quality Stocks That Just Raised Their Dividends

10 High-Quality Stocks That Just Raised Their Dividends

These blue-chip stocks are rewarding shareholders with higher income and have strong long-term outlooks.

AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion To Treat Adolescents With Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease

AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion To Treat Adolescents With Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease

- If approved by the European Commission, HUMIRA will be the first and only treatment option for patients aged 12 and older with hidradenitis suppurativa (HS), a painful, chronic inflammatory skin disease.

Check Out These 15 Stocks With Solid Dividend Yields

Check Out These 15 Stocks With Solid Dividend Yields

Here are 15 stocks that boast solid dividend yields and are growing earnings.

How to Play Rising Treasury Yields

How to Play Rising Treasury Yields

Check out these 15 stocks that boast solid dividend yields and are growing earnings.

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.

AbbVie Stock Higher on Humira Patent Win

AbbVie Stock Higher on Humira Patent Win

The Patent Trial and Appeal Board has denied Coherus's petition to make a copy of AbbVie's Humira drug.

AbbVie Receives FDA Orphan Drug Designation For Investigational Medicine Veliparib For The Treatment Of Advanced Squamous Non-Small Cell Lung Cancer

AbbVie Receives FDA Orphan Drug Designation For Investigational Medicine Veliparib For The Treatment Of Advanced Squamous Non-Small Cell Lung Cancer

- Veliparib in combination with chemotherapy or radiation is being investigated in ongoing studies for advanced squamous non-small cell lung cancer (NSCLC)[1]

AbbVie To Showcase Growing Oncology Portfolio And Commitment To Treating Blood Cancers At The 2016 American Society Of Hematology Annual Meeting

AbbVie To Showcase Growing Oncology Portfolio And Commitment To Treating Blood Cancers At The 2016 American Society Of Hematology Annual Meeting

- Results to be presented from ibrutinib clinical studies across multiple blood cancers

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.